Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Swiss National Bank

Swiss National Bank cut its position in Hologic, Inc. (NASDAQ:HOLX) by 0.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 692,740 shares of the medical equipment provider’s stock after selling 2,200 shares during the quarter. Swiss National Bank’s holdings in Hologic were worth $56,431,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in HOLX. Price T Rowe Associates Inc. MD grew its stake in shares of Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after acquiring an additional 2,753,016 shares in the last quarter. Swedbank AB purchased a new position in Hologic in the first quarter valued at about $120,827,000. Black Creek Investment Management Inc. grew its stake in Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Hologic in the 2nd quarter valued at approximately $39,427,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

HOLX stock opened at $78.57 on Wednesday. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The stock has a market capitalization of $18.25 billion, a price-to-earnings ratio of 23.59, a PEG ratio of 2.48 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock’s fifty day moving average is $80.56 and its two-hundred day moving average is $78.30.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the firm posted $0.89 EPS. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Finally, Leerink Partners reduced their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.